Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2022
COVID-19 vaccine weekly safety report (27 January 2022)
27 January 2022 - To 23 January 2022, the TGA has received 431 reports which have been assessed as likely to ...
Posted by Michael Wonder on 24 Jan 2022
TGA approves MSD's Vaxneuvance
24 January 2022 - Vaxneuvance (pneumococcal 15 valent conjugate vaccine (CRM197 protein)) was approved on 17 January 2022 for active ...
Posted by Michael Wonder on 23 Jan 2022
ATAGI statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
24 January 2022 - ATAGI recommends that Novavax COVID-19 vaccine can be used for the primary course of COVID-19 vaccination ...
Posted by Michael Wonder on 20 Jan 2022
COVID-19 vaccine weekly safety report (20 January 2022)
20 January 2022 - To 16 January 2022, the TGA has received 428 reports which have been assessed as likely to ...
Posted by Michael Wonder on 20 Jan 2022
Statement on the arrival of the Novavax vaccine and COVID-19 pills
20 January 2022 - Medicines Australia welcomes the TGA’s provisional approval for the Novavax COVID-19 vaccine and the provisional approval ...
Posted by Michael Wonder on 20 Jan 2022
TGA provisionally approves Novavax (Biocelect) COVID-19 vaccine Nuvaxovid
20 January 2022 - The Therapeutic Goods Administration has granted provisional approval to Biocelect (on behalf of Novavax) for its ...
Posted by Michael Wonder on 19 Jan 2022
Lieutenant General John Frewen says he expects TGA approval of Novavax vaccine is 'imminent'
19 January 2022 - The head of Australia's vaccine rollout expects one to two per cent of Australians who remain unvaccinated ...
Posted by Michael Wonder on 17 Jan 2022
TGA recognises the Gamaleya Institute vaccine (Sputnik V, Russian Federation) for international travel to Australia
17 January 2022 - Today, the TGA determined that an additional COVID-19 vaccine, the two dose course of the Gamaleya ...
Posted by Michael Wonder on 17 Jan 2022
ATAGI update following weekly COVID-19 meeting (12 January 2022)
17 January 2022 - Previously, severely immunocompromised people aged 12 years and older were recommended to receive a third primary dose ...
Posted by Michael Wonder on 16 Jan 2022
COVID-19 vaccine weekly safety report (13 January 2022)
13 January 2022 - To 9 January 2022, the TGA has received 952 reports which have been assessed as likely to ...
Posted by Michael Wonder on 16 Jan 2022
COVID-19 vaccine weekly safety report (6 January 2022)
17 January 2022 - To 2 January 2022, the TGA has received 415 reports which have been assessed as likely to ...
Posted by Michael Wonder on 28 Dec 2021
COVID-19 vaccine weekly safety report (23 December 2021)
23 December 2021 - To 19 December 2021, the TGA has received 415 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 Dec 2021
ATAGI update following weekly COVID-19 meeting (15 December 2021)
18 December 2021 - On Wednesday 15 December 2021 ATAGI reviewed the latest developments relating to COVID-19 and COVID-19 vaccine safety. ...
Posted by Michael Wonder on 16 Dec 2021
COVID-19 vaccine weekly safety report (16 December 2021)
16 December 2021 - To 12 December 2021, the TGA has received approximately 290 reports of suspected adverse events identified as ...
Posted by Michael Wonder on 13 Dec 2021
Moderna vaccine deal to produce 100 million doses in Melbourne reached by Federal and Victorian Governments
13 December 2021 - Australia is poised to become the largest producer of mRNA vaccines outside the US and Europe ...